BriaCell publishes investor presentation on Bria-IMT Phase 3 metastatic breast cancer program

• Briacell highlighted an ongoing pivotal Phase 3 Bria-ABC trial of Bria-IMT regimen with a checkpoint inhibitor in advanced breast cancer.
• Primary endpoint overall survival; interim analysis set at 144 events with a BLA submission trigger if hazard ratio is ≤ 0.6.
• Phase 2 combination data: median progression-free survival 3.6 months for the Phase 3 formulation; 2.6 months for an IFNγ-treated formulation.
• Randomized Phase 2 overall survival: 13.3 months for the Phase 3 sequence; 16.6 months for the Phase 3 formulation and sequence.
• Company cited 71% intracranial objective response rate in evaluable patients with CNS metastases; planned CNS subgroup analysis in Phase 3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.